GlassScriptPhysician profile
Howard Coke
NPI 1811349095
$1,840.92
in general payments reported to CMS, 2019-2025
24 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.19 · 2021: $148 · 2022: $396 · 2023: $411 · 2024: $659 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.04 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $445.06 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $170.88 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $154.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $149.41 | 2022-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $133.73 | 2021-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $108.24 | 2021-2023 | Lupkynis |
| Opko Pharmaceuticals, LLC | $97.12 | 2022-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $91.82 | 2022-2025 | Tarpeyo |
| Amgen INC. | $69.83 | 2022-2024 | Krystexxa |
| Pharmacosmos Therapeutics INC. | $49.67 | 2022 | |
| Daiichi Sankyo INC. | $47.98 | 2022 | |
| Ani Pharmaceuticals, INC. | $34.68 | 2023 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $34.15 | 2021-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.60 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $33.43 | 2022-2024 | Benlysta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.35 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $27.14 | 2019 | |
| Horizon Therapeutics Plc | $25.56 | 2023 | Krystexxa |
| B. Braun Medical INC. | $23.38 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.25 | 2025 | Acthar |
| Ardelyx, INC. | $18.85 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $17.34 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.20 | 2022 | |
| Travere Therapeutics, INC. | $4.74 | 2023-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Coke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.